Ying Wang
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Oncology top 5%
- Cancer Cells and Metastasis
Papers in
-
- Circular RNAs in diseases 13
- Pluripotent Stem Cells Research 11
- CRISPR and Genetic Engineering 10
- Co-authors
- Jin Sun (1 shared paper)Guo ShiRong (1 shared paper)Knut Stavem (1 shared paper)Xue‐Ying He (1 shared paper)Sjur Humerfelt (1 shared paper)Sheng Shu (1 shared paper)Qijun Qian (12 shared papers)Fredrik A. Dahl (1 shared paper)
- Journals
- PLoS ONE (7 papers)Medicine (6 papers)Oncotarget (5 papers)Journal of Clinical Oncology (5 papers)Scientific Reports (4 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Ying Wang
294 papers receiving 4.8k citations
Ying Wang's Hit Papers
Peers
Comparison fields: 5 of 173
- Cancer Research 810
- Oncology 696
- Pulmonary and Respiratory Medicine 802
- Hepatology 184
- Molecular Biology 1.7k
Countries citing papers authored by Ying Wang
This map shows the geographic impact of Ying Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Wang more than expected).
Fields of papers citing papers by Ying Wang
This network shows the impact of papers produced by Ying Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Wang. The network helps show where Ying Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Ying Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 313 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Biliary cancer: Utility of next‐generation sequencing for clinical management Hit paper breakdown → | 2016 | 300 |
| 2 | 2008 | 130 | |
| 3 | 2013 | 110 | |
| 4 | 2006 | 107 | |
| 5 | 2019 | 106 | |
| 6 | 2022 | 106 | |
| 7 | 2006 | 92 | |
| 8 | 2014 | 89 | |
| 9 | 2020 | 84 | |
| 10 | 2019 | 84 | |
| 11 | 2013 | 81 | |
| 12 | 2015 | 76 | |
| 13 | 2003 | 68 | |
| 14 | 2017 | 62 | |
| 15 | 2023 | 60 | |
| 16 | 2019 | 60 | |
| 17 | 2010 | 59 | |
| 18 | 2015 | 58 | |
| 19 | 2013 | 55 | |
| 20 | 2014 | 53 |
About Ying Wang
Ying Wang is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Epidemiology and Surgery, having authored 313 papers that have together received 4.9k indexed citations. Recurring topics across this work include Virus-based gene therapy research (16 papers), Hepatocellular Carcinoma Treatment and Prognosis (15 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers), Circular RNAs in diseases (13 papers), Pluripotent Stem Cells Research (11 papers), MicroRNA in disease regulation (11 papers), CRISPR and Genetic Engineering (10 papers) and Hepatitis B Virus Studies (9 papers). The work is most often cited by research in Cancer Research (810 citations), Oncology (696 citations), Pulmonary and Respiratory Medicine (802 citations), Hepatology (184 citations) and Molecular Biology (1.7k citations). Ying Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jin Sun, Guo ShiRong, Knut Stavem, Xue‐Ying He, Sjur Humerfelt, Sheng Shu, Qijun Qian, Fredrik A. Dahl, Liwei Wang and Milind Javle. Their work appears in journals such as PLoS ONE, Medicine, Oncotarget, Journal of Clinical Oncology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.